Cargando…

Targeting PI3K/mTOR Signaling in Cancer

Detalles Bibliográficos
Autor principal:	Arcaro, Alexandre
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4001057/ https://www.ncbi.nlm.nih.gov/pubmed/24795861 http://dx.doi.org/10.3389/fonc.2014.00084

Ejemplares similares

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Targeting the PI3K-AKT-mTOR signaling network in cancer
por: Khan, Khurum H., et al.
Publicado: (2013)

SPR965, a Dual PI3K/mTOR Inhibitor, as a Targeted Therapy in Ovarian Cancer
por: Tran, Arthur-Quan, et al.
Publicado: (2021)

CAMK1D Inhibits Glioma Through the PI3K/AKT/mTOR Signaling Pathway
por: Jin, Qianxu, et al.
Publicado: (2022)

Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers
por: Reddy, Dhanasekhar, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
por: Li, Huayi, et al.
Publicado: (2021)

PI3K/Akt/mTOR Signaling Pathway: Role in Esophageal Squamous Cell Carcinoma, Regulatory Mechanisms and Opportunities for Targeted Therapy
por: Luo, Qian, et al.
Publicado: (2022)

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease
por: Liu, Yang, et al.
Publicado: (2018)

PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
por: Peng, Yan, et al.
Publicado: (2022)

HRK inhibits colorectal cancer cells proliferation by suppressing the PI3K/AKT/mTOR pathway
por: Wang, Haowei, et al.
Publicado: (2022)

Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
por: Conciatori, Fabiana, et al.
Publicado: (2022)

Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells
por: Vadlakonda, Lakshmipathi, et al.
Publicado: (2013)

Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway
por: Guo, Jida, et al.
Publicado: (2022)

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
por: Glaviano, Antonino, et al.
Publicado: (2023)

PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
por: Li, Xiaoman, et al.
Publicado: (2016)

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis
por: Reilly, R., et al.
Publicado: (2017)

Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
por: Bang, Jieun, et al.
Publicado: (2023)

PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
por: Zhu, Kunrui, et al.
Publicado: (2022)

Corrigendum: Hinokiflavone Inhibits Growth of Esophageal Squamous Cancer By Inducing Apoptosis via Regulation of the PI3K/AKT/mTOR Signaling Pathway
por: Guo, Jida, et al.
Publicado: (2022)

OCT4 induces EMT and promotes ovarian cancer progression by regulating the PI3K/AKT/mTOR pathway
por: Xie, Weiwei, et al.
Publicado: (2022)

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
por: Zhou, S, et al.
Publicado: (2014)

Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer
por: Zhang, Jing, et al.
Publicado: (2021)

GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway
por: Wang, Lei, et al.
Publicado: (2022)

RAC3 Inhibition Induces Autophagy to Impair Metastasis in Bladder Cancer Cells via the PI3K/AKT/mTOR Pathway
por: Wang, Liwei, et al.
Publicado: (2022)

Therapeutic targets for cancer: Current concepts with PI 3-K, Akt, & mTOR
por: Maiese, Kenneth
Publicado: (2013)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma
por: Matsuoka, Tasuku, et al.
Publicado: (2014)

AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV
por: Bhatt, Aadra P., et al.
Publicado: (2013)

Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs
por: Markman, Ben, et al.
Publicado: (2010)

Effect of VEGFR, PDGFR and PI3K/mTOR Targeting in Glioblastoma
por: PURCARU, S.O., et al.
Publicado: (2015)

Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme
por: Yao, Weiqi, et al.
Publicado: (2021)

Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
por: Colardo, Mayra, et al.
Publicado: (2021)

Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC
por: Moore, Gillian, et al.
Publicado: (2021)

Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
por: Sun, Eun Jin, et al.
Publicado: (2021)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway
por: Papoff, Giuliana, et al.
Publicado: (2023)

PI3K/AKT/mTOR Pathway in Angiogenesis
por: Karar, Jayashree, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_7un08fpuc2vplvag104fcgksmt